CytomX Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Cash & Equivalents	18.09	194.57	206.45	192.78	189.34	248.49	178.47	105.56	60.74	64.5
Short-Term Investments	157.34	0	99.7	124.26	107.72	188.55	196.56	77.29	126.89	0
Cash & Cash Equivalents	175.43	194.57	306.14	317.04	297.06	437.04	375.03	182.86	187.63	64.5
Cash Growth	-9.84%	-36.45%	-3.44%	6.72%	-32.03%	16.54%	105.10%	-2.54%	190.91%	-
Receivables	3.43	35.99	0.79	0.8	0.01	0.1	10.14	2.31	0.74	1.88
Other Current Assets	4.08	6.55	3.37	6.18	6.26	8.33	3.44	2.98	1.38	0.48
Total Current Assets	182.94	237.1	310.3	324.01	303.34	445.48	388.6	188.15	189.75	66.85
Property, Plant & Equipment	16.18	21.02	25.32	29.45	32.75	6.93	4.22	4.39	3.48	3.02
Goodwill and Intangibles	1.68	1.82	1.97	2.12	2.26	2.41	2.55	2.7	2.7	2.7
Other Long-Term Assets	1	0.94	1.82	3.09	2.93	2.29	2.27	3.89	1.28	0.49
Total Long-Term Assets	18.86	23.79	29.11	34.65	37.95	11.63	9.04	10.98	7.46	6.21
Total Assets	201.79	260.89	339.41	358.66	341.28	457.11	397.64	199.13	197.22	73.06
Accounts Payable	1.46	2.81	2.82	3	4.16	5.13	4.21	6.6	4.7	1.92
Deferred Revenue	212.32	301.33	284.76	318.71	230.24	277.98	305.26	104.15	60.83	66.96
Current Debt	4.59	4.08	0	0	0	0	0	0	0	1.42
Other Current Liabilities	-62.45	-155.61	-209.71	-253.59	-148.81	-185.2	-248.32	-74.98	-49.79	-59.14
Total Current Liabilities	155.91	152.61	77.87	68.11	85.59	97.91	61.15	35.77	15.74	11.16
Long-Term Debt	9.39	13.98	18.06	21.68	24.87	0	0	0	0	1.57
Other Long-Term Liabilities	83.94	180.06	243.94	276.65	179.71	228.32	266.6	84.88	55.41	62.16
Total Long-Term Liabilities	93.33	194.03	262	298.33	204.58	228.32	266.6	84.88	55.41	63.73
Total Liabilities	249.24	346.64	339.87	366.44	290.17	326.23	327.75	120.65	71.15	74.89
Total Debt	13.97	18.06	18.06	21.68	24.87	0	0	0	0	2.99
Debt Growth	-22.61%	0.01%	-16.70%	-12.85%	-	-	-	-	-	-
Retained Earnings	-723.45	-722.88	-623.56	-507.69	-417.23	-314.98	-219.47	-176.37	-117.47	-78.14
Comprehensive Income	0.1	0.01	-0.24	-0.05	0.06	-0.09	-0.09	-0.03	-0.08	0
Shareholders' Equity	-47.45	-85.75	-0.46	-7.77	51.11	130.88	69.9	78.48	126.07	-78.54
Net Cash / Debt	161.45	176.51	288.09	295.36	272.19	437.04	375.03	182.86	187.63	61.51
Net Cash / Debt Growth	-8.53%	-38.73%	-2.46%	8.51%	-37.72%	16.54%	105.10%	-2.54%	205.04%	-
Net Cash Per Share	2.19	2.68	4.49	6.40	6.00	10.49	10.09	5.05	21.83	62.16
Working Capital	27.02	84.49	232.43	255.9	217.75	347.57	327.45	152.38	174.02	55.69
Book Value Per Share	-0.64	-1.30	-0.01	-0.17	1.13	3.14	1.88	2.17	14.67	-79.38

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).